Arrow Exploration Corp.

Arrow Exploration Corp has confirmed up to four hydrocarbon-bearing zones at the Icaco 3 well in Colombia's Tapir Block, opening almost 10 additional development locations across the Ubaque, Guadalupe and Carbonera C7 intervals. The IC-HZ4 and IC-HZ5 horizontal wells encountered a record Ubaque thickness of over 100 feet containing 13.7 API crude, with the Ubaque trend extending across the northern part of the block. Arrow is preparing to skid its rig and drill continuously until at least June next year, with current production above 5,000 barrels of oil equivalent per day expected to move well north of that level. The company remains cash-flow positive above its capital expenditure, and CEO Marshall Abbott said the current oil price environment supports a more aggressive drilling stance. On the Tapir Block licence extension, Abbott described recent dialogue with Colombia's national regulator and Ecopetrol as very positive, with a decision expected before year-end.

Arrow Exploration Corp has brought its Icaco-2 well in Colombia on production at around 830 barrels per day gross, taking total corporate output to approximately 5,000 barrels of oil equivalent per day. CEO Marshall Abbott says the Icaco discovery may be material to Arrow, with horizontal and vertical development wells already planned. Frontier IP Group PLC has raised £4 million through a placing and subscription at 12p per share, with six directors participating in the subscription element, and a retail offer through BookBuild aims to raise a further £400,000 before closing at 5pm on 18 June. RC365 Holding PLC has signed a point-of-sale agreement with StarCruises International to deploy its RC3.0 payments platform across cruise operations in Asia, including cryptocurrency acceptance and multi-language support. Coiled Therapeutics has appointed two senior oncologists to a newly formed medical advisory board guiding its lead cancer drug AO-252 through phase I trials, with Professor Guru Sonpavde and Dr Alexander Spira shaping clinical strategy as the programme moves toward expansion cohorts in the second half of 2026. Genflow Biosciences Ltd has been invited to present results from its SLAB dog longevity study at the Animal Longevity Summit in Toronto in October, with the study evaluating its SIRT6 gene therapy in aged beagles concluding this month. Pan African Resources PLC will join the FTSE 250 from 23 June, following the court sanction of its all-share acquisition of Emmerson Resources, and also joins the FTSE 350, FTSE All-Share and related indices.